Begin main content

Lonsurf for Metastatic Colorectal Cancer – Details

Project Number pCODR 10122
Brand Name Lonsurf
Generic Name Trifluridine and Tipiracil
Tumour Type Gastointestinal
Indication Metastatic Colorectal Cancer
Funding Request For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents
Review Status Pending
Pre Noc Submission Yes
NOC Date
Manufacturer Taiho Pharma Canada, Inc.
Submitter Taiho Pharma Canada, Inc.
Submission Date (Target Date) November 6, 2017
Submission Type New Drug
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡ November 20, 2017
Check-point meeting (target date)
pERC Meeting (target date)
Clarification The Submitter notified pCODR that they will be unable to submit by their original target date and an updated target submission date has been provided.
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.